drug interaction(s) of aspirin, P2Y12 inhibitors & anticoagulants
Jump to navigation
Jump to search
Indications
- acute coronary syndrome, myocardial infarction or coronary stent in a patient with venous thromboembolism or atrial fibrillation
Drug interactions
Management
- dual therapy with P2Y12 inhibitor + direct oral anticoagulant as effective for reducing thromboembolic events with less risk of bleeding[2][3]
More general terms
References
- ↑ 1.0 1.1 Fiedler KA et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol 2015 Apr 28; 65:1619 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25908066
- ↑ 2.0 2.1 2.2 Link MS Which Anticoagulation Strategy for Patients with Atrial Fibrillation and a New Stent? NEJM Journal Watch. Nov 14, 2016 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016 Nov 14 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27959713 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1611594 - ↑ 3.0 3.1 3.2 Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377:1513-1524. October 19, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28844193 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1708454